Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veraxa Biotech AG - Ordinary Shares
(NQ:
VRXA
)
2.010
+0.210 (+11.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
823,539
Open
1.890
Bid (Size)
1.980 (6,000)
Ask (Size)
2.040 (100)
Prev. Close
1.800
Today's Range
1.860 - 2.280
52wk Range
1.700 - 27.36
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
July 27, 2026
Via
Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
July 27, 2026
Via
Investor Brand Network
Performance
YTD
-91.9%
-91.9%
1 Month
-7.4%
-7.4%
3 Month
-91.9%
-91.9%
6 Month
-91.9%
-91.9%
1 Year
-91.9%
-91.9%
More News
Read More
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
July 24, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
July 23, 2026
Via
Investor Brand Network
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
July 23, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
July 22, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
July 20, 2026
Via
Investor Brand Network
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
July 20, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
July 14, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
July 13, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
July 13, 2026
Via
Investor Brand Network
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
July 13, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
July 10, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
July 08, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
July 06, 2026
Via
Investor Brand Network
BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 06, 2026
Via
Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 06, 2026
Via
Investor Brand Network
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
July 06, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
July 02, 2026
Via
Investor Brand Network
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
July 02, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
July 01, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals
June 29, 2026
Via
Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
June 24, 2026
Via
Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
June 24, 2026
Via
Investor Brand Network
Frequently Asked Questions
Is Veraxa Biotech AG - Ordinary Shares publicly traded?
Yes, Veraxa Biotech AG - Ordinary Shares is publicly traded.
What exchange does Veraxa Biotech AG - Ordinary Shares trade on?
Veraxa Biotech AG - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Veraxa Biotech AG - Ordinary Shares?
The ticker symbol for Veraxa Biotech AG - Ordinary Shares is VRXA on the Nasdaq Stock Market
What is the current price of Veraxa Biotech AG - Ordinary Shares?
The current price of Veraxa Biotech AG - Ordinary Shares is 2.010
When was Veraxa Biotech AG - Ordinary Shares last traded?
The last trade of Veraxa Biotech AG - Ordinary Shares was at 07/27/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.